[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354702-105":59,"doc-detail-354702-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-genomic-analysis-of-her2-mutant-metastatic-triple-negative-breast-cancer-treated-with-neratinib-alone-or-with-trastuzumab-in-the-summit-basket-trial","Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial","","Human epidermal growth factor receptor 2 (HER2) mutations occur in 1% to 3% of triple-negative breast cancers (TNBC), offering a biomarker-directed treatment target. In the SUMMIT basket trial (NCT01953926), patients with HER2-mutant, metastatic TNBC received neratinib alone or neratinib plus trastuzumab, and final outcomes were evaluated. Primary and secondary efficacy endpoints assessed objective response and clinical benefit, while ctDNA was explored longitudinally. Confirmed response rates and progression-free survival favored the combination, and sequencing showed treatment-associated ctDNA dynamics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-genomic-analysis-of-her2-mutant-metastatic-triple-negative-breast-cancer-treated-with-neratinib-alone-or-with-trastuzumab-in-the-summit-basket-trial/354702/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-genomic-analysis-of-her2-mutant-metastatic-triple-negative-breast-cancer-treated-with-neratinib-alone-or-with-trastuzumab-in-the-summit-basket-trial/354702.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this SUMMIT basket trial analysis?","Question",{"text":112,"@type":113},"To assess efficacy and generate genomic insights for HER2-mutant metastatic TNBC treated with neratinib alone versus neratinib plus trastuzumab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were treatment responses evaluated in this study?",{"text":117,"@type":113},"The primary endpoint was investigator-assessed objective response rate at the first post-baseline tumor assessment, with additional measures including confirmed response rate, clinical benefit rate, and progression-free survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What did circulating tumor DNA (ctDNA) sequencing reveal?",{"text":121,"@type":113},"Serial ctDNA variant allele frequencies decreased with response or stable disease and increased with progression, and sequencing identified emergence or increases in on-pathway (ERBB3) and off-pathway (KRAS and TP53) mutations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354702,1790167368,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial  \nKomal Jhaveri1,2, Lisa D. Eli3, Sara A. Hurvitz4, Adam Brufsky5, Ron Bose6, Mara de Miguel7, Nisha Unni8, Sonya Reid9, David I. Quinn10,11, Devalingam Mahalingam12, Cristina Saura Manich13, Jos ´Angel Garc´ıa-Senz14, Alejandro Mart´ınez-Bueno15, Angel Guerrero-Zotano16,17, Olivier Trdan18, Hans Wildiers19, Georg F. Bischof20, Judith Bebchuk20, and David B. Solit1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Human epidermal growth factor receptor 2 (HER2) mutations occur in 1% to 3% of triple-negative breast cancers (TNBC), representing a novel target for biomarker-directed treatment. In the SUMMIT basket trial (NCT01953926), patients with HER2-mutant, metastatic TNBC received neratinib (240 mg/day) orneratinib + trastuzumab (N + T; neratinib 240 mg/day, intravenous trastuzumab 8 mg/kg initially and then 6 mg/kg every 3 weeks). Wereport final results from the neratinib and N + T TNBC cohorts.\u003Cbr>Patients and Methods: Primary endpoint: investigatorassessed objective response rate at first postbaseline tumor assessment (ORRfirst); secondary endpoints included confirmed ORR by investigator, clinical benefit rate (CBR), and progression-free survival (PFS); exploratory endpoint included circulating tumor DNA (ctDNA) collected at baseline, during treatment, and at the end of treatment.\u003Cbr>Results: Twenty-seven patients were enrolled between July 2014 and September 2021. Confirmed ORRs were 40%[95% confidence interval (CI), 12.2􀀁73.8] for neratinib (n ¼ 10) and 35.3%(95% CI,\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14.2􀀁61.7) for N + T (n ¼ 17). CBRs were 40%(95% CI, 12.2􀀁73.8) and 47.1%(95% CI, 23􀀁72.2), respectively; median PFS times were 2.89 (95% CI, 0.95􀀁5.52) and 6.24 months (95% CI, 2.10􀀁8. 18), respectively. HER2 mutation variant allele frequencies in ctDNA from patients with response or stable disease decreased upon treatment and increased upon progression. Serial ctDNA sequencing revealed emergence or increase in on-pathway (ERBB3) and off-pathway (KRAS and TP53) mutations. The most common treatment-emergent adverse events were diarrhea, nausea, and constipation.\u003Cbr>Conclusions: N + T in patients with HER2-mutant metastatic TNBC seemed to prolong responses versus neratinib alone, representing a novel approach for patients with biomarker-defined metastatic TNBC. Based on these and previously published data, neratinib-based combinations are endorsed by the National Comprehensive Cancer Network guidelines for patients with hormone receptor–positive or –negative metastatic breast cancer with activating HER2 mutations.\u003Cbr>See related commentary by Lloyd et al., p. 3715 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTriple-negative breast cancer (TNBC), which represents approxim","cbCaiu6VnXWoTLlD","https://ap.wps.com/l/cbCaiu6VnXWoTLlD","pdf",1512344,11,"English","# Purpose\n# Patients and Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the main goal of this SUMMIT basket trial analysis?\",\"answer\":\"To assess efficacy and generate genomic insights for HER2-mutant metastatic TNBC treated with neratinib alone versus neratinib plus trastuzumab.\"},{\"question\":\"How were treatment responses evaluated in this study?\",\"answer\":\"The primary endpoint was investigator-assessed objective response rate at the first post-baseline tumor assessment, with additional measures including confirmed response rate, clinical benefit rate, and progression-free survival.\"},{\"question\":\"What did circulating tumor DNA (ctDNA) sequencing reveal?\",\"answer\":\"Serial ctDNA variant allele frequencies decreased with response or stable disease and increased with progression, and sequencing identified emergence or increases in on-pathway (ERBB3) and off-pathway (KRAS and TP53) mutations.\"}]","Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial | PDF",1790113095,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c3468b949a01a017b8201e57926cac2.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60394dbd6809d06db47da6e3940c2083.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7adf35d770abe0f22651e4196508a43.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/adb56a99836e238fade32eb690e3d2ac.webp",980,1311]